IONIS PHARMACEUTICALS INC (IONS)
US4622221004 - Common Stock
Taking everything into account, IONS scores 3 out of 10 in our fundamental rating. IONS was compared to 588 industry peers in the Biotechnology industry. IONS scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. While showing a medium growth rate, IONS is valued expensive at the moment.
1. Profitability
1.1 Basic Checks
IONS had negative earnings in the past year.
In the past year IONS has reported a negative cash flow from operations.
IONS had negative earnings in 4 of the past 5 years.
In multiple years IONS reported negative operating cash flow during the last 5 years.
1.2 Ratios
With an excellent Return On Assets value of -12.25%, IONS belongs to the best of the industry, outperforming 88.57% of the companies in the same industry.
IONS has a Return On Equity of -94.72%. This is comparable to the rest of the industry: IONS outperforms 46.59% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -12.25% | ||
| ROE | -94.72% | ||
| ROIC | N/A |
ROA(3y)-8%
ROA(5y)-6.8%
ROE(3y)-48.5%
ROE(5y)-37.28%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
IONS has a Gross Margin of 98.85%. This is amongst the best in the industry. IONS outperforms 99.15% of its industry peers.
In the last couple of years the Gross Margin of IONS has remained more or less at the same level.
The Profit Margin and Operating Margin are not available for IONS so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 98.85% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.16%
GM growth 5Y-0.17%
2. Health
2.1 Basic Checks
IONS does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for IONS has been increased compared to 1 year ago.
The number of shares outstanding for IONS has been increased compared to 5 years ago.
The debt/assets ratio for IONS has been reduced compared to a year ago.
2.2 Solvency
IONS has an Altman-Z score of 1.36. This is a bad value and indicates that IONS is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of 1.36, IONS is in the better half of the industry, outperforming 66.72% of the companies in the same industry.
IONS has a Debt/Equity ratio of 3.18. This is a high value indicating a heavy dependency on external financing.
IONS's Debt to Equity ratio of 3.18 is on the low side compared to the rest of the industry. IONS is outperformed by 83.11% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 3.18 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 1.36 |
ROIC/WACCN/A
WACC7.82%
2.3 Liquidity
A Current Ratio of 5.90 indicates that IONS has no problem at all paying its short term obligations.
IONS has a Current ratio of 5.90. This is in the better half of the industry: IONS outperforms 61.77% of its industry peers.
A Quick Ratio of 5.83 indicates that IONS has no problem at all paying its short term obligations.
IONS has a Quick ratio of 5.83. This is in the better half of the industry: IONS outperforms 61.77% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 5.9 | ||
| Quick Ratio | 5.83 |
3. Growth
3.1 Past
IONS shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 11.42%, which is quite good.
Looking at the last year, IONS shows a very strong growth in Revenue. The Revenue has grown by 34.08%.
IONS shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 5.60% yearly.
EPS 1Y (TTM)11.42%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q95.59%
Revenue 1Y (TTM)34.08%
Revenue growth 3Y2.6%
Revenue growth 5Y5.6%
Revenue growth Q2Q113.63%
3.2 Future
IONS is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 25.97% yearly.
Based on estimates for the next years, IONS will show a very strong growth in Revenue. The Revenue will grow by 22.74% on average per year.
EPS Next Y-59.22%
EPS Next 2Y-14.72%
EPS Next 3Y7.26%
EPS Next 5Y25.97%
Revenue Next Year-0.4%
Revenue Next 2Y10.22%
Revenue Next 3Y18.67%
Revenue Next 5Y22.74%
3.3 Evolution
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
IONS reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year IONS is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-14.72%
EPS Next 3Y7.26%
5. Dividend
5.1 Amount
No dividends for IONS!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
IONIS PHARMACEUTICALS INC
NASDAQ:IONS (5/2/2024, 7:00:27 PM)
After market: 43.09 0 (0%)43.09
+0.08 (+0.19%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap6.28B
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -12.25% | ||
| ROE | -94.72% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 98.85% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.26
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 3.18 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 5.9 | ||
| Quick Ratio | 5.83 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)11.42%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y-59.22%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)34.08%
Revenue growth 3Y2.6%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y